← Leaderboards
Tony L Yaksh
University Of Arizona
$23,138,803
Attributed
$29,724,046
Total exposure
23
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,724,046 · 23
By mechanism
R01$21,975,942 · 9
R37$2,552,925 · 1
R21$1,595,044 · 3
P30$1,469,784 · 3
R41$916,526 · 2
T32$492,639 · 1
Top collaborators
- Yury Miller11 shared
- Veronica Shubayev6 shared
- Alex Y Strongin6 shared
- Satheesh B Ravula3 shared
- Patrick M Dougherty2 shared
- Rivkah R Isseroff2 shared
- Eric A. Johnson2 shared
- Sabine Pellett2 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Frank Porreca$26,550,739
- Hemant S Kudrimoti$631,948
- Michael H Ossipov$409,776
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingPainSpinal CordSpinalInflammationCellsReceptorHyperalgesiaAcuteChronic PainBaseResponseAnalgesicsInjuryNeuronsPreventIn VivoLeadAgonistNerve InjuryChronicInflammatoryPersistent PainInhibitor/Antagonist
Grant awards (96)
Role of TLR4-lipid rafts in nociception$702,049
R01 · FY2025 · NS · contact PI
NEURAXIAL AAVS TARGETING DRG CHANNELS INVOLVED IN CHRONIC POST INFLAMMATORY PAIN$561,031
R01 · FY2025 · NS · contact PI
Role of TLR4-lipid rafts in nociception$801,239
R01 · FY2024 · NS · contact PI
NEURAXIAL AAVS TARGETING DRG CHANNELS INVOLVED IN CHRONIC POST INFLAMMATORY PAIN$621,963
R01 · FY2024 · NS · contact PI
AIBP and regulation of neuropathic pain$443,771
R01 · FY2021 · NS
Sex, Stress and Immunity in the Acute to Chronic Pain Transition$332,894
R01 · FY2021 · NS · contact PI
AIBP and regulation of neuropathic pain$443,771
R01 · FY2020 · NS
Reversal of preexisting neuropathic pain by spinal delivery of AIBP$376,652
R33 · FY2020 · NS
Sex, Stress and Immunity in the Acute to Chronic Pain Transition$332,894
R01 · FY2020 · NS · contact PI
AIBP and regulation of neuropathic pain$787,291
R01 · FY2019 · NS
Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.$646,527
R41 · FY2019 · NS · contact PI
AIBP and regulation of neuropathic pain$443,771
R01 · FY2019 · NS
Reversal of preexisting neuropathic pain by spinal delivery of AIBP$369,856
R21 · FY2019 · NS
Sex, Stress and Immunity in the Acute to Chronic Pain Transition$332,894
R01 · FY2019 · NS · contact PI
AIBP and regulation of neuropathic pain$443,771
R01 · FY2018 · NS
Reversal of preexisting neuropathic pain by spinal delivery of AIBP$380,298
R21 · FY2018 · NS
Sex, Stress and Immunity in the Acute to Chronic Pain Transition$337,129
R01 · FY2018 · NS · contact PI
New Approach to Atopic Dermatitis$225,000
R43 · FY2018 · AR
Characterization of Toxicity with Spinal Opiates$520,798
R01 · FY2017 · DA · contact PI
AIBP and regulation of neuropathic pain$443,771
R01 · FY2017 · NS
Sex, Stress and Immunity in the Acute to Chronic Pain Transition$335,878
R01 · FY2017 · NS · contact PI
Sex, Stress and Immunity in the Acute to Chronic Pain Transition$98,425
R01 · FY2017 · NS · contact PI
Proteolysis of Myelin as a Source of Neuropathic Pain$687,775
R01 · FY2016 · DE
Characterization of Toxicity with Spinal Opiates$515,589
R01 · FY2016 · DA · contact PI
Proteolysis of Myelin as a Source of Neuropathic Pain$100,000
R01 · FY2016 · DE
Proteolysis of Myelin as a Source of Neuropathic Pain$693,414
R01 · FY2015 · DE
Characterization of Toxicity with Spinal Opiates$512,985
R01 · FY2015 · DA · contact PI
Construction and Analysis of BoNT derivatives as Pain Specific Inhibitors$230,996
R21 · FY2015 · AI
Proteolysis of Myelin as a Source of Neuropathic Pain$696,603
R01 · FY2014 · DE
Characterization of Toxicity with Spinal Opiates$534,548
R01 · FY2014 · DA · contact PI
The Pharmacology of Spinal Analgesics$299,730
R01 · FY2014 · DA · contact PI
Discovery of novel small molecule analgesics$244,999
R41 · FY2014 · NS
Construction and Analysis of BoNT derivatives as Pain Specific Inhibitors$205,506
R21 · FY2014 · AI
I-Corps training for 1R41NS086244-A01 Discovery of novel small molecule analgesics$25,000
R41 · FY2014 · NS
Proteolysis of Myelin as a Source of Neuropathic Pain$670,052
R01 · FY2013 · DE
The Pharmacology of Spinal Analgesics$287,741
R01 · FY2013 · DA · contact PI
Proteolysis of Myelin as a Source of Neuropathic Pain$760,582
R01 · FY2012 · DE
Pain Evoked Release of Amino Acids and Prostanoids$378,525
R37 · FY2012 · NS · contact PI
The Pharmacology of Spinal Analgesics$299,730
R01 · FY2012 · DA · contact PI
The role of selective brain penetrating GRPR antagonists in pruritis.$184,000
R21 · FY2012 · NS
Pain Evoked Release of Amino Acids and Prostanoids$378,525
R37 · FY2011 · NS · contact PI
The Pharmacology of Spinal Analgesics$299,730
R01 · FY2011 · DA · contact PI
The role of selective brain penetrating GRPR antagonists in pruritis.$224,388
R21 · FY2011 · NS
Pain Evoked Release of Amino Acids and Prostanoids$386,250
R37 · FY2010 · NS · contact PI
Characterization of Toxicity with Spinal Opiates$337,266
R01 · FY2010 · DA · contact PI
The Pharmacology of Spinal Analgesics$309,000
R01 · FY2010 · DA · contact PI
Pain Evoked Release of Amino Acids and Prostanoids$77,034
R37 · FY2010 · NS · contact PI
Characterization of Toxicity with Spinal Opiates$340,673
R01 · FY2009 · DA · contact PI
Pain Evoked Release of Amino Acids and Prostanoids$337,544
R37 · FY2009 · NS · contact PI
The Pharmacology of Spinal Analgesics$287,127
R01 · FY2009 · DA · contact PI
Characterization of Toxicity with Spinal Opiates$340,673
R01 · FY2008 · DA · contact PI
Pain Evoked Release of Amino Acids and Prostanoids$337,544
R37 · FY2008 · NS · contact PI
The Pharmacology of Spinal Analgesics$287,127
R01 · FY2008 · DA · contact PI
Characterization of Toxicity with Spinal Opiates$347,625
R01 · FY2007 · DA · contact PI
Pain Evoked Release of Amino Acids and Prostanoids$337,544
R37 · FY2007 · NS · contact PI
The Pharmacology of Spinal Analgesics$292,988
R01 · FY2007 · DA · contact PI
Pain Evoked Release of Amino Acids and Prostanoids$319,959
R37 · FY2006 · NS · contact PI
The Pharmacology of Spinal Analgesics$301,332
R01 · FY2006 · DA · contact PI
Pain Mechanisms and the Development of Analgesics$15,000
R13 · FY2006 · DA · contact PI
Spinal Galanin and its Receptors in Pain Processing$406,662
R01 · FY2005 · NS
Characterization of Toxicity with Spinal Opiates$304,000
R01 · FY2005 · DA
The Pharmacology of Spinal Analgesics$299,054
R01 · FY2005 · DA
PAIN EVOKED RELEASE OF AMINO ACIDS AND PROSTANOIDS$285,668
R01 · FY2005 · NS
Neurobiology of Pain$106,262
T32 · FY2005 · NS
Spinal Galanin and its Receptors in Pain Processing$396,366
R01 · FY2004 · NS
PAIN EVOKED RELEASE OF AMINO ACIDS AND PROSTANOIDS$326,121
R01 · FY2004 · NS
Characterization of Toxicity with Spinal Opiates$304,000
R01 · FY2004 · DA
Neurobiology of Pain$106,262
T32 · FY2004 · NS
Spinal Galanin and its Receptors in Pain Processing$47,301
R01 · FY2004 · NS
PAIN EVOKED RELEASE OF AMINO ACIDS AND PROSTANOIDS$41,332
R01 · FY2004 · NS
Spinal Galanin and its Receptors in Pain Processing$333,174
R01 · FY2003 · NS
Characterization of Toxicity with Spinal Opiates$304,000
R01 · FY2003 · DA
PAIN EVOKED RELEASE OF AMINO ACIDS AND PROSTANOIDS$285,959
R01 · FY2003 · NS
Neurobiology of Pain$101,130
T32 · FY2003 · NS
PAIN EVOKED RELEASE OF AMINO ACIDS AND PROSTANOIDS$40,304
R01 · FY2003 · NS
Spinal Galanin and its Receptors in Pain Processing$336,467
R01 · FY2002 · NS
PAIN EVOKED RELEASE OF AMINO ACIDS AND PROSTANOIDS$286,094
R01 · FY2002 · NS
SPINAL ACTION OF OPIATES$272,461
R01 · FY2002 · DA
CANCER SYMPTOM CONTROL$183,723
P30 · FY2002 · CA
DEVELOPMENTAL FUNDS$183,723
P30 · FY2002 · CA
DEVELOPMENTAL FUNDS$183,723
P30 · FY2002 · CA
DEVELOPMENTAL FUNDS$183,723
P30 · FY2002 · CA
CANCER SYMPTOM CONTROL$183,723
P30 · FY2002 · CA
CANCER SYMPTOM CONTROL$183,723
P30 · FY2002 · CA
Neurobiology of Pain$12,358
T32 · FY2002 · NS
SPINAL ACTION OF OPIATES$264,528
R01 · FY2001 · DA
DEVELOPMENTAL FUNDS$183,723
P30 · FY2001 · CA
CANCER SYMPTOM CONTROL$183,723
P30 · FY2001 · CA
NEUROBIOLOGY OF PAIN$78,870
T32 · FY2001 · NS
PILOT--PRECLINICAL SAFETY STUDIES FOR INTRATHECAL DPDPE$0
P01 · FY2001 · DA
DEVELOPMENTAL FUNDS$0
P30 · FY2001 · CA
CANCER SYMPTOM CONTROL$0
P30 · FY2001 · CA
SPINAL ACTION OF OPIATES$256,821
R01 · FY2000 · DA
PILOT--PRECLINICAL SAFETY STUDIES FOR INTRATHECAL DPDPE$104,534
P01 · FY2000 · DA
NEUROBIOLOGY OF PAIN$87,757
T32 · FY2000 · NS
NEOPLASM /CANCER PALLATIVE CARE$0
P30 · FY2000 · CA